| Literature DB >> 33498631 |
Claudio Salaris1, Melania Scarpa2, Marina Elli3, Alice Bertolini1, Simone Guglielmetti4, Fabrizio Pregliasco5, Corrado Blandizzi6, Paola Brun1, Ignazio Castagliuolo1.
Abstract
SARS-CoV-2 is a newly emerging virus that currently lacks curative treatments. Lactoferrin (LF) is a naturally occurring non-toxic glycoprotein with broad-spectrum antiviral, immunomodulatory and anti-inflammatory effects. In this study, we assessed the potential of LF in the prevention of SARS-CoV-2 infection in vitro. Antiviral immune response gene expression was analyzed by qRT-PCR in uninfected Caco-2 intestinal epithelial cells treated with LF. An infection assay for SARS-CoV-2 was performed in Caco-2 cells treated or not with LF. SARS-CoV-2 titer was determined by qRT-PCR, plaque assay and immunostaining. Inflammatory and anti-inflammatory cytokine production was determined by qRT-PCR. LF significantly induced the expression of IFNA1, IFNB1, TLR3, TLR7, IRF3, IRF7 and MAVS genes. Furthermore, LF partially inhibited SARS-CoV-2 infection and replication in Caco-2 intestinal epithelial cells. Our in vitro data support LF as an immune modulator of the antiviral immune response with moderate effects against SARS-CoV-2 infection.Entities:
Keywords: COVID-19; SARS-CoV-2; antiviral immunity; lactoferrin
Mesh：
Substances：
Year: 2021 PMID： 33498631 PMCID： PMC7911668 DOI： 10.3390/nu13020328
Source DB: PubMed Journal: Nutrients ISSN： 2072-6643 Impact factor: 5.717